secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0000950170-25-072594
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo reports 90% remission rate in frontline AML with mipletamig triplet; no CRS
--------------------------------------------------------------------------------

- 9 of 10 frontline AML patients achieved remission with mipletamig + venetoclax + azacitidine across two trials.
- RAINIER Cohort 2 fully enrolled; Cohort 3 now open; 5/6 patients in Cohort 1 achieved remission within 30 days.
- No cytokine release syndrome observed in ongoing RAINIER trial; favorable safety profile attributed to ADAPTIR format.
- Financial results for Q1 2025 reported but no specific figures disclosed in this release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000095017025072594/0000950170-25-072594-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000095017025072594/apvo-20250515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-072594

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer